A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Cetrelimab (Primary) ; Gemcitabine (Primary)
- Indications Bladder cancer; Carcinoma; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms SunRISe-4
- Sponsors Janssen Research & Development; Janssen-Cilag
- 08 Oct 2024 Planned End Date changed from 16 Mar 2027 to 7 Mar 2027.
- 08 Oct 2024 Planned primary completion date changed from 1 Dec 2026 to 19 Feb 2025.
- 16 Sep 2024 According to a Janssen Media Release, interim data from this study were featured as a late-breaking oral presentation at the European Society of Medical Oncology (ESMO) 2024 Congress.